+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pressure Ulcers - Pipeline Review, H1 2020

  • ID: 4997701
  • Drug Pipelines
  • February 2020
  • Region: Global
  • 32 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • EyeGene Inc
  • MimeTech Srl
  • NovaLead Pharma Pvt Ltd
  • Obatala Sciences Inc
  • Shionogi & Co Ltd
  • Topadur Pharma AG
  • MORE
Pressure Ulcers - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Pressure Ulcers - Pipeline Review, H1 2020, provides an overview of the Pressure Ulcers (Dermatology) pipeline landscape.

Pressure ulcers are an injury that breaks down the skin and underlying tissue. The parts of the body most at risk of developing pressure ulcers are those that are not covered by a large amount of body fat and are in direct contact with a supporting surface (bed or a wheelchair). Causes include continuous pressure, friction and shear. Treatment includes antibiotics and nutrition.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Pressure Ulcers - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Pressure Ulcers (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pressure Ulcers (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Pressure Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 2 and 4 respectively.

Pressure Ulcers (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pressure Ulcers (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Pressure Ulcers (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pressure Ulcers (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pressure Ulcers (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pressure Ulcers (Dermatology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pressure Ulcers (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pressure Ulcers (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • EyeGene Inc
  • MimeTech Srl
  • NovaLead Pharma Pvt Ltd
  • Obatala Sciences Inc
  • Shionogi & Co Ltd
  • Topadur Pharma AG
  • MORE
Introduction
Report Coverage
Pressure Ulcers - Overview
Pressure Ulcers - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Pressure Ulcers - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Pressure Ulcers - Companies Involved in Therapeutics Development
EyeGene Inc
MimeTech Srl
NovaLead Pharma Pvt Ltd
Obatala Sciences Inc
Shionogi & Co Ltd
Topadur Pharma AG
Pressure Ulcers - Drug Profiles
EG-Decorin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NLP-328 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SR-0379 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Pressure Ulcers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TOPN-53 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udonitrectag - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Pressure Ulcers - Dormant Projects
Pressure Ulcers - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Pressure Ulcers, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pressure Ulcers - Pipeline by EyeGene Inc, H1 2020
Pressure Ulcers - Pipeline by MimeTech Srl, H1 2020
Pressure Ulcers - Pipeline by NovaLead Pharma Pvt Ltd, H1 2020
Pressure Ulcers - Pipeline by Obatala Sciences Inc, H1 2020
Pressure Ulcers - Pipeline by Shionogi & Co Ltd, H1 2020
Pressure Ulcers - Pipeline by Topadur Pharma AG, H1 2020
Pressure Ulcers - Dormant Projects, H1 2020
Pressure Ulcers - Discontinued Products, H1 2020

List of Figures
Number of Products under Development for Pressure Ulcers, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • EyeGene Inc
  • MimeTech Srl
  • NovaLead Pharma Pvt Ltd
  • Obatala Sciences Inc
  • Shionogi & Co Ltd
  • Topadur Pharma AG
Note: Product cover images may vary from those shown
Adroll
adroll